Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS


ABSTRACT
Rationale Platelets play an active role in the pathogenesis of acute respiratory distress syndrome (ARDS). Animal and observational studies have shown aspirin’s antiplatelet and immunomodulatory effects may be beneficial in ARDS.

Objective To test the hypothesis that aspirin reduces inflammation in clinically relevant human models that recapitulate pathophysiological mechanisms implicated in the development of ARDS.

Methods Healthy volunteers were randomised to receive placebo or aspirin 75 or 1200 mg (1:1:1) for seven days prior to lipopolysaccharide (LPS) inhalation, in a double-blind, placebo-controlled, allocation-concealed study. Bronchoalveolar lavage (BAL) was performed 6 hours after inhaling 50 μg of LPS. The primary outcome measure was BAL IL-8. Secondary outcome measures included markers of alveolar inflammation (BAL neutrophils, cytokines, neutrophil proteases), alveolar epithelial cell injury, systemic inflammation (neutrophils and plasma C-reactive protein (CRP)) and platelet activation (thromboxane B2, TXB2). Human lungs, perfused and ventilated ex vivo (EVLP) were randomised to placebo or 24 mg aspirin and injured with LPS. BAL was carried out 4 hours later. Inflammation was assessed by BAL differential cell counts and histological changes.

Results In the healthy volunteer (n=33) model, data for the aspirin groups were combined. Aspirin did not reduce BAL IL-8. However, aspirin reduced pulmonary neutrophilia and tissue damaging neutrophil proteases (Matrix Metalloproteinase (MMP)-8/-9), reduced BAL concentrations of tumour necrosis factor α and reduced systemic and pulmonary TXB2. There was no difference between high-dose and low-dose aspirin. In the EVLP model, aspirin reduced BAL neutrophilia and alveolar injury as measured by histological damage.

Conclusions These are the first prospective human data indicating that aspirin inhibits pulmonary neutrophilic inflammation, at both low and high doses. Further clinical studies are indicated to assess the role of aspirin in the prevention and treatment of ARDS.

Trial registration number NCT01659307
Results

INTRODUCTION
The acute respiratory distress syndrome (ARDS) is characterised by an uncontrolled alveolar inflammatory response, the hallmarks of which are neutrophil infiltration, protein-rich pulmonary oedema accumulation, hypoxia and the need for mechanical ventilation. Platelets may contribute to the pathophysiology of ARDS. Platelet activation, degranulation and aggregation within the lung can lead to further vasodilatation, with chemoattraction of neutrophils and monocytes, increasing coagulation and the deposition of a provisional matrix, and inducing fibroblast activation and proliferation, all features of ARDS.

Additionally, the formation of neutrophil or monocyte-platelet aggregates can drive inflammation: neutrophils seek out activated platelets within the circulation and interact with them via PSGL-1—a glycoprotein ligand for P-selectin—to initiate inflammation. This process is implicated directly in several in vivo models of acute lung injury, including acid-induced Acute Lung Injury (ALI) and lipopolysaccharide (LPS)-induced injury.

Recently, platelets have also been shown to play an important role in the formation of neutrophil-extracellular traps (NETs). NETs formation allows activated neutrophils to release chromatin material interlaced with granular proteins...
and proteases, which traps pathogens but also damages endothelial cells and drives neutrophil recruitment to the lungs.\(^7\) An increase in NETs has been detected in plasma of patients with transfusion-related ARDS\(^8\) and is also implicated in the pathophysiology of ARDS of other aetiologies.\(^8,9\)

Aspirin is widely used as a highly effective antiplatelet in the primary and secondary prevention of cerebrovascular, coronary artery and peripheral vascular disease. In addition to its antiplatelet effects, it increases the production of resolvins and lipoxins, which may reduce inflammation and promote resolution.\(^10\) Various experimental studies of ARDS have shown a beneficial effect of aspirin on reducing pulmonary inflammation.\(^11\) Similarly, in observational studies, patients on aspirin therapy prior to hospitalisation had a reduced incidence of ARDS\(^12\) and organ dysfunction\(^14\). In contrast, the recent LIPS-A study, which prospectively treated patients at risk of developing ARDS with aspirin, showed no reduction in incidence of ARDS.\(^15\) The study had limitations, with a lower incidence of ARDS than expected, and the population was much less ill, with a lower incidence of mechanical ventilation, acute kidney injury and mortality, than predicted. As such the study was underpowered for the primary and secondary endpoints. In addition, over half the screened potentially eligible population was excluded due to pre-existing antiplatelet use or pre-existing bilateral infiltrates. The authors acknowledged that the study was underpowered and concluded the exclusion of large cohorts significantly limited the generalisability of the findings. In a single-centre observational study, we found use of aspirin (at antiplatelet doses) in patients with ARDS either prior to or during their Intensive Care Unit (ICU) stay was associated with a reduction in ICU mortality.\(^16\)

Most animal studies have used a higher dose of aspirin, while observational studies have reported a beneficial effect with 75–81 mg of aspirin.\(^12\) There have been no prospective experimental studies testing whether aspirin can directly affect inflammation within the human lung (LIPS-A addressed only markers of systemic inflammation\(^15\)) or whether high or low doses are necessary to attenuate pulmonary inflammation in humans.

The objective of this study was to test if aspirin can reduce pulmonary inflammation in two human models of ARDS and to identify if high-dose aspirin was more effective than low dose in reducing pulmonary inflammation.

Inhalation of LPS has been previously shown to produce pulmonary inflammation, which is qualitatively representative of ARDS without any associated serious adverse outcomes,\(^17\) and has been used to test anti-inflammatory or pro-repair interventions to inform clinical trials for the prevention or treatment of ARDS.\(^17\) The model of injuring isolated perfused and ventilated human lungs ex vivo allows the testing of anti-inflammatory therapeutics in a human setting, with the advantages of being able to use a more injurious stimulus than in the healthy volunteer-inhaled LPS model, and allowing histological examination.\(^18-20\)

Instilling LPS in this ex vivo lung perfusion (EVLP) model drives neutrophilic pulmonary inflammation, impaired fluid clearance and elevation in bronchoalveolar lavage (BAL) concentrations of the pro-inflammatory cytokines that characterise ARDS.\(^18\)

In this study, we show that aspirin reduces neutrophilic pulmonary inflammation and that low-dose and high-dose aspirin have similar effects within the pulmonary compartment.

**METHODS**

**In vivo model of pulmonary inflammation in healthy volunteers**

The study, the effect of aspirin on reducing inflammation in a human in vivo model of acute lung injury (ARENA), was registered at ClinicalTrials.gov (NCT01659307) and was approved by the local research ethics committee (ORECNI).

Volunteers

Thirty-five healthy non-smoking subjects, taking no regular medication, recruited by advertising, underwent screening assessment (history, physical examination, routine blood investigation, ECG and spirometry).

Exclusion criteria were age <18 years, pregnancy, breast feeding or female of childbearing potential not taking adequate contraception, participation in a clinical trial of an investigational medicinal product within 30 days, aspirin or non-steroidal anti-inflammatory use in the past four weeks, history of asthma, known aspirin or non-steroidal anti-inflammatory drug hypersensitivity, history of peptic ulcer disease, platelet count <150×10^9/mL, known aspirin resistance.

The study was carried out in the Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility at Belfast City Hospital.

**Study design**

This was a randomised, double-blinded, placebo-controlled allocation-concealed clinical study in which subjects were randomised to aspirin 1200 mg, 75 mg or placebo (1:1:1). Randomisation was undertaken by an independent clinical trials pharmacist using the statistical software nQuery Advisor. Mixed block sizes (of 3, 6 and 9) and no stratification were used. Blinding was achieved by encapsulation with gelatin. The aspirin capsule contained the aspirin tablet with lactose powder. The placebo capsule contained lactose powder only. Both aspirin and placebo study drugs had an identical appearance. Subjects took the study medication for 7 days before inhalation of LPS. On day 7, 30 min after the study medicine was taken under direct observation by the study team, subjects inhaled 50 μg LPS (O26:B6, Sigma) using an automated nebulizer (Spira dosimeter, Finland) as previously described.\(^17\)

Blood was collected immediately before the subject inhaled the LPS and also at 6 and 24 hours after LPS inhalation. BAL was performed 6 hours after LPS inhalation, at which point we have previously identified a robust neutrophilic inflammatory response. Processing of BAL fluid (BALF) and blood was performed as described previously.\(^17\) The study schedule is summarised in online supplementary figure S1 in the appendix.

The primary outcome of the study was BAL interleukin (IL)-8 concentration. The sample size was calculated as 11 per group to detect a 30% change in BAL IL-8, with 80% power at two-tailed significance of <0.05, with aspirin. This was based on a previous study where BAL IL-8 concentration after LPS inhalation by healthy volunteers was 389±94 pg/mL,\(^17\) and evidence that aspirin reduced systemic IL-8 by up to 30% in a cohort of patients undergoing dialysis.\(^22\) The main secondary efficacy outcomes were markers of alveolar inflammatory response (BAL neutrophil counts, BAL inflammatory cytokines), alveolar epithelial injury (albumin, protein permeability ratio, SP-D and MMP-7) and plasma inflammatory response as assessed by CRP 24 hours after LPS inhalation.

**EVLP model**

This model was adapted from the methods described by Lee et al.\(^18\) Briefly, lungs obtained from the International Institute for the Advancement of Medicine, with consent for use in research, were perfused, rewarmed with Dulbecco’s Modified Eagle Medium (DMEM) with 1-glutamine and 5% albumin (perfusate) and inflated with 10 cm H_2O CPAP. BAL was carried...
out at baseline once a temperature of 35°C was reached. Whole blood (100 mL) obtained from a healthy volunteer was incubated for 1 hour with 24 mg aspirin and added to the perfusate (giving a final concentration of aspirin of 21 μg/mL in the perfusate, which corresponds to peak plasma levels obtained after a 300 mg dose). Simultaneously LPS (6 mg) was introduced into a preselected lobe. At 4 hours, BAL was repeated. Experiments were carried out for six lungs in the placebo group and five lungs in the aspirin-treated group.

The use of human lungs and blood was approved by Queen’s University of Belfast School of Medicine, Dentistry and Biomedical Sciences Research Ethics Committee. The study schedule is shown in online supplementary figure S2. A detailed description of the EVLP model is included in the online supplementary data.

The investigator carrying out the laboratory analyses was kept blinded to the treatment assignment group of the normal volunteers or the ex vivo lungs throughout.

**BAL cytokines and proteases**

These were measured using cytometric bead array or ELISA as previously described and are detailed in the online supplementary data.

**BAL protein and permeability measurements**

Total protein was measured by Bradford assay. BAL albumin was measured by an immunoturbidimetric method by Randox Testing Services, UK. IgG was measured by ELISA (Immundiagnostik). Protein permeability ratio was expressed as ratio of BAL IgG:total protein.

**Neutrophil extracellular traps**

To quantify NETs in human plasma, a capture ELISA based on Neutrophil Elastase (NE) associated with DNA was used. A detailed description is provided in the online supplementary data.

**Leucocyte platelet aggregates**

Neutrophil-platelet and monocyte-platelet aggregates were measured in blood at baseline and 6 hours after LPS inhalation as previously described. A detailed description is provided in the online supplementary data.

**Phagocytosis assay**

Neutrophils isolated from peripheral blood were allowed to adhere to tissue culture plastic for 30 min prior to treatment with aspirin (0.1 or 0.5 mM). Cells were then exposed to autologous serum-opsonised zymosan for 30 min, washed with PBS, air dried, fixed with methanol and stained with Giemsa to determine the percentage of neutrophils containing two or more zymosan particles. Further details are given in the online supplementary data.

**Lung injury severity score**

Lung sections from the injured lobes in the EVLP model were examined histologically. Details of the scoring system are given in the online supplementary data. The scorer was blinded to the group allocation.

**Statistical analysis**

In the healthy volunteer study, the a priori plan was to present and compare data from the combined aspirin-treated groups with placebo. A secondary analysis to determine if results in the high-dose and low-dose groups differed was carried out. There were no planned interim analyses. Aspirin and placebo groups were compared by Mann-Whitney U (MWU) test. Data for the EVLP study were analysed using GraphPad Prism (GraphPad Software; San Diego, California, USA). A p value of ≤0.05 was considered significant.

**RESULTS**

Thirty-five healthy subjects were randomised; two withdrew before progressing to LPS inhalation and bronchoscopy (one decided not to proceed with the study, and one developed an upper respiratory tract infection (URT), so LPS inhalation and bronchoscopy were considered inappropriate). Randomisation continued until 33 volunteers completed the study protocol. There were 13 in the placebo cohort and 10 in each aspirin cohort (n=20 aspirin in total) (figure 1). Baseline parameters including age, sex, body mass index or lung volumes are shown in table 1.

Aspirin was well tolerated with no increased incidence of adverse effects in the aspirin-treated cohort. There were no significant changes in FEV₁, FVC, oxygen saturation measured by pulse oximetry or vital signs over the course of the study. There were no serious adverse events or suspected unexpected serious adverse reactions to trigger an unscheduled data monitoring committee meeting. A detailed description of the monitoring and adverse events (see online supplementary table S1, ST1) experienced by the volunteers is included in the online supplementary data.

**Aspirin reduces BAL neutrophilia but not BAL IL-8**

Aspirin pretreatment did not significantly reduce the prespecified primary outcome measure IL-8 (figure 2A). However, aspirin reduced neutrophil count in the BAL fluid of healthy volunteers who inhaled LPS (figure 2B). There was no significant change in BAL macrophage or lymphocyte counts (table 2), nor BAL NETs—data not shown.

**Aspirin reduces neutrophil-derived enzyme secretion in the alveolar space**

Having established that aspirin reduces BAL neutrophilia in the human lung in response to LPS, we investigated the effect on markers of neutrophil activity. The neutrophil-specific enzyme MMP-8 was significantly reduced in the aspirin-treated group (figure 3A). MMP-9, also secreted by activated neutrophils (and other cells), was significantly reduced in the aspirin-treated group (figure 3B). The major secreted inhibitors of these MMPs, Tissue Inhibitors of Metalloproteinase (TIMPs)-1/-2, were unaffected by aspirin treatment (see online supplementary figure S3A and S3B). Both myeloperoxidase (MPO) and neutrophil elastase (NE) showed a trend to reduction in response to aspirin (figure 3C, D) but this did not reach statistical significance.

**Aspirin reduces BAL TNFα in healthy volunteers who have inhaled LPS**

To investigate the effect of aspirin on the inflammatory milieu of the LPS-injured alveolus, we measured key cytokines that drive injury in ARDS. Aspirin reduced BAL concentrations of the inflammatory cytokine TNFα (table 3). There was a non-statistically significant trend towards reduction in all other measured pro-inflammatory cytokines, particularly IL-6, p=0.07 (table 3). The IL-1β:IL-1Ra ratio, a functional marker of unopposed IL-1β activity was reduced but again did not reach statistical significance (table 3). Aspirin had no effect on BAL CRP.
Aspirin did not affect epithelial barrier function in response to LPS

Aspirin had no effect on epithelial barrier function as measured by BAL total protein (not shown), albumin (figure 4A) or IgG: total protein ratio (figure 4B). Interestingly, aspirin also had no effect on secretion of the type II epithelial specific marker SP-D (figure 4C), nor on MMP-7, an epithelial-derived protease in the alveolus (figure 4D).

The effect of aspirin on systemic inflammatory response

While there was a trend towards a reduction in peripheral neutrophil count, and in peripheral NET formation in the aspirin-treated group 6 hours after LPS inhalation these did not reach significance (figure 5A, p=0.068, and figure 5B, p=0.086). Aspirin did not reduce peripheral CRP (see online supplementary data figure S4), nor peripheral leucocyte platelet aggregate (LPA) formation (see online supplementary figure S5). Importantly when human primary neutrophils were treated with aspirin in vitro,

Table 1  Baseline characteristics of healthy volunteers inhaling lipopolysaccharide

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Placebo</th>
<th>Aspirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>24±4</td>
<td>27±10</td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>35</td>
<td>53</td>
</tr>
<tr>
<td>Body mass index</td>
<td>23±3</td>
<td>25±3</td>
</tr>
<tr>
<td>FEV₁ (L)</td>
<td>3.8±1</td>
<td>4.1±1</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>4.4±1</td>
<td>4.9±1</td>
</tr>
</tbody>
</table>

Figure 1  CONSORT diagram of healthy volunteer trial. BAL, bronchoalveolar lavage; LPS, lipopolysaccharide.

Figure 2  Aspirin reduces bronchoalveolar lavage (BAL) interleukin (IL)-8 in the healthy volunteer model of lipopolysaccharide (LPS)-induced lung injury, but does reduce neutrophil recruitment to the alveolar space. Healthy human subjects were randomised to placebo (n=13) or aspirin (n=20) for 7 days prior to LPS inhalation (50 μg) and underwent BAL 6 hours later. (A) IL-8 was measured in BAL fluid, but was not significantly reduced, p=0.11 (B) Neutrophils in BAL fluid were counted on cytocentrifuge and were reduced by over a third in the aspirin-treated group (estimated difference in median=0.8×10⁵/mL, 95% CIs 0.06 to 2.1; *p=0.03 for aspirin vs placebo).
aspirin did not impede neutrophil phagocytosis (see online supplementary data figure S6).

**Aspirin reduces BAL and systemic thromboxane B2 levels**
Consistent with its known effect of circulating platelets, volunteers in the aspirin-treated groups had reduced plasma concentrations of thromboxane B2 (figure 6A). Interestingly, aspirin treatment was also associated with a significant reduction in BAL thromboxane B2 concentrations also (figure 6B).

**High-dose versus low-dose aspirin in the human healthy volunteer model**
The a priori statistical analysis plan was to combine data from the aspirin-treated cohorts and compare with placebo. A secondary analysis of high-dose versus low-dose aspirin showed no consistent difference between the two groups (table 4). For neutrophil-derived enzymes, MPO was lower in the high-dose aspirin group, while NE was lower in the 75 mg aspirin group.

**Aspirin reduces BAL neutrophils and histological injury score in the ex vivo perfused and injured lung**
Consistent with its effects in the healthy volunteer model of LPS inhalation, aspirin reduced BAL neutrophilia in human lungs injured with LPS ex vivo (figure 7A) and reduced evidence of lung injury as assessed at histological examination (figure 7B, C). Aspirin did not improve alveolar fluid clearance (AFC), a marker of intact epithelial function, in the ex vivo injured lung (not shown).

**DISCUSSION**
While prior preclinical and observational studies have indicated aspirin may have beneficial effects in ARDS, these are the first prospective data indicating a beneficial effect on alveolar inflammation in human subjects, and the first data showing aspirin reduces histological alveolar injury in human lungs.

Aspirin did not significantly reduce the prespecified primary outcome measure of BAL IL-8 concentration. In this study, the SD of BAL IL-8 in healthy donors after LPS inhalation was higher than we have found in a previous study and the study was therefore underpowered for this outcome measure. Interestingly while aspirin did not significantly reduce IL-8, it did reduce neutrophil infiltration to the alveolar space in both the healthy volunteer study and the EVLP model, suggesting other mediators of neutrophil chemoattraction were affected.

Aspirin reduced BAL concentrations of neutrophil-specific protease MMP-8 as well as MMP-9. Both of these proteases are

**Table 2 BAL Differential Cell Count**

<table>
<thead>
<tr>
<th>Bronchoalveolar lavage</th>
<th>Placebo</th>
<th>Aspirin</th>
<th>Difference in median (95% CIs)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrophages (×10⁵/mL)</td>
<td>2.99 (2.30–4.24)</td>
<td>2.96 (1.44–3.71)</td>
<td>0.4 (−0.71 to 1.49)</td>
<td>0.45</td>
</tr>
<tr>
<td>Lymphocytes (×10⁷/mL)</td>
<td>0.40 (0.26–0.62)</td>
<td>0.35 (0.20–0.80)</td>
<td>0.05 (−0.18 to 0.25)</td>
<td>0.65</td>
</tr>
</tbody>
</table>

**Figure 3** Aspirin reduces neutrophil proteases in the bronchoalveolar lavage (BAL) fluid of healthy volunteers who have inhaled lipopolysaccharide (LPS). BAL as in figure 2A was analysed for neutrophil granular enzymes. (a) Aspirin significantly reduced BAL MMP-8 (difference in median 2.2 ng/mL, 95% CI 0.15 to 4.45; *p=0.04 for aspirin (n=20) vs. placebo (n=13)). (B) Aspirin significantly reduced BAL MMP-9 (difference in medians 14.2 ng/mL, 95% CI 1.0 to 29.8; *p=0.04 for aspirin (n=20) vs. placebo (n=13)). (C) Aspirin did not significantly reduce MPO (n=20) versus control (n=13) (difference in median 12.4 ng/mL, 95% CI −6.6 to 52.6; p=0.19). (D) Aspirin (n=20) did not statistically significantly reduce BAL neutrophil elastase compared with placebo (n=13) (median difference 4.5 ng/mL, 95% CI −3.0 to 26.4; p=0.30).
present in preformed states within neutrophils, in the secondary (MMP-8) and tertiary granules (MMP-9). While MMP-9 is also secreted by other cells within the alveolus, including epithelial cells and macrophages, the neutrophil is recognised to be a major source of its production in ARDS. The reduction in these proteases implies that in addition to reduced overall numbers of neutrophils in the alveolar space in the aspirin-treated group, there are less degranulated neutrophils here also. A reduction in MMP-9 and MMP-8 may reduce tissue injury in the early stages of alveolar injury.

LPS inhalation drives activation of TLR-4 and downstream activation of nuclear factor κB (NFκB)-dependent cytokine production. Aspirin significantly reduced secretion of the pro-inflammatory cytokine TNFα. Macrophage-derived TNFα has long been identified as a key factor driving activation of neutrophils in ARDS. In vivo models show that selective inhibition of the pro-inflammatory signalling TNFR1 (p55) reduces neutrophil recruitment and injury in acid—and ventilator-induced lung ARDS. A trend to reduction in secretion of the other major pro-inflammatory cytokines implicated in ARDS (including IL-6 and IL1β net activity as assessed by IL-1β:IL-1Ra ratio) was seen but did not reach statistical significance. Aspirin in experimental studies has been shown to attenuate activation of NFκB by inhibiting IκB kinase, which may be a potential mechanism of reduction in the secretion of pro-inflammatory cytokines seen in this study.

Importantly, although aspirin had a clear effect on neutrophilic inflammation in this model it did not have any obvious effect on epithelial barrier function, as assessed by protein leak. Altered neutrophil infiltration to the alveolus in response to injury without changes in epithelial barrier function has been reported by other investigators, suggesting that the two processes, both pathophysiological hallmarks of ARDS, may be differentially regulated. SP-D is reduced in the alveolar space in ARDS, and in our study aspirin had no effect on this type II epithelial cell marker implying aspirin does not exert its effect

<table>
<thead>
<tr>
<th>BAL analyte</th>
<th>Placebo</th>
<th>Aspirin</th>
<th>Difference in median (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNFα (pg/mL)</td>
<td>106 (87–154)</td>
<td>78 (52–128)</td>
<td>33 (1.91 to 63.74)</td>
<td>0.03</td>
</tr>
<tr>
<td>IL-1β (pg/mL)</td>
<td>43 (26–99)</td>
<td>37 (19–55)</td>
<td>13 (−6 to 46)</td>
<td>0.17</td>
</tr>
<tr>
<td>IL-1β:IL-1Ra</td>
<td>0.02 (0.01–0.03)</td>
<td>0.01 (0.008–0.014)</td>
<td>0.01 (−0.001 to 0.02)</td>
<td>0.07</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>857 (606–1263)</td>
<td>648 (330–835)</td>
<td>258 (−40 to 526)</td>
<td>0.07</td>
</tr>
<tr>
<td>IL-8 (pg/mL)</td>
<td>448 (321–657)</td>
<td>346 (275–508)</td>
<td>102 (−40 to 253)</td>
<td>0.11</td>
</tr>
<tr>
<td>MCP-1 (pg/mL)</td>
<td>547 (412–1055)</td>
<td>502 (348–888)</td>
<td>83 (−168 to 363)</td>
<td>0.45</td>
</tr>
<tr>
<td>CRP (pg/mL)</td>
<td>332 (93–1140)</td>
<td>308 (114–824)</td>
<td>9 (−351 to 266)</td>
<td>0.99</td>
</tr>
</tbody>
</table>

IL, interleukin; TNFα, tumour necrosis factor α; MCP, Monocyte chemoattractant protein.

Figure 4 Aspirin does not reduce alveolar leak nor markers of epithelial injury/activation in bronchoalveolar lavage (BAL) in healthy volunteers who have inhaled lipopolysaccharide. BAL as in figure 2 was analysed for (A) albumin as a marker of alveolar barrier integrity and (B) IgG:total protein ratio. Neither was affected by aspirin pretreatment. For albumin, difference in medians was 9.7 mg/L, 95% CIs −23.5 to 41.2. For IgG:total, protein difference in medians was 0.02, 95% CIs −0.01 to 0.04. (C) Aspirin did not affect BAL SP-D, a marker of type II alveolar epithelial cell activation; difference in medians 8.4 ng/mL, 95% CIs −0.5 to 19.5. (D) Aspirin did not reduce BAL MMP-7, an epithelial cell-derived protease in the alveolar space; difference in medians 0.2 ng/mL, 95% CIs −0.7 to 1.0). n=13 for placebo, n=20 for aspirin for all measures.

The effect of aspirin on peripheral neutrophil count. (A) Peripheral neutrophil count in healthy volunteers 6 hours after lipopolysaccharide (LPS) inhalation is not significantly reduced by aspirin, difference in medians 1.47×10^6/mL, 95% CIs −0.1 to 3.4, p=0.07. (B) Neutrophil extracellular trap (NET) formation in blood 6 hours after LPS inhalation was not statistically significantly reduced in the aspirin-treated cohort (n=20) versus placebo (n=13). One outlier from the placebo group is not shown within the range of the graph (value >7000 pg/mL), but is included in statistical analysis presented. Difference in medians 41 pg/mL, 95% CIs 14.7 to 64.3; *p=0.003. Aspirin 75 mg Aspirin 1200 mg

<table>
<thead>
<tr>
<th></th>
<th>Aspirin 75 mg</th>
<th>Aspirin 1200 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophils (x10^9/mL)</td>
<td>1.6 (1.3–2.8)</td>
<td>1.5 (1.2–1.7)</td>
</tr>
<tr>
<td>MMP-8 (ng/mL)</td>
<td>3.4 (2.3–4.8)</td>
<td>2.6 (1.9–4.0)</td>
</tr>
<tr>
<td>MMP-9 (ng/mL)</td>
<td>33.7 (27.1–50.1)</td>
<td>33.7 (16.1–44.4)</td>
</tr>
<tr>
<td>MPO (ng/mL)</td>
<td>38.6 (29.2–53.3)</td>
<td>25.2 (17.5–34.6)</td>
</tr>
<tr>
<td>NE (ng/mL)</td>
<td>10.6 (6.0–15.6)</td>
<td>21.1 (11.1–36.1)</td>
</tr>
<tr>
<td>TNFx (pg/mL)</td>
<td>77 (51–100)</td>
<td>90 (49–141)</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>563 (368–880)</td>
<td>782 (284–901)</td>
</tr>
<tr>
<td>IL-8 (pg/mL)</td>
<td>308 (264–431)</td>
<td>397 (269–515)</td>
</tr>
<tr>
<td>MCP-1 (pg/mL)</td>
<td>497 (385–967)</td>
<td>502 (289–924)</td>
</tr>
<tr>
<td>IL-1β (pg/mL)</td>
<td>46 (30–66)</td>
<td>30 (16–38)</td>
</tr>
<tr>
<td>IL-1Ra (pg/mL)</td>
<td>3000 (2413–4182)</td>
<td>2266 (1700–3682)</td>
</tr>
<tr>
<td>TIMP-1 (pg/mL)</td>
<td>2155 (1431–3783)</td>
<td>2243 (1275–3789)</td>
</tr>
<tr>
<td>TIMP-2 (pg/mL)</td>
<td>566 (495–912)</td>
<td>574 (224–805)</td>
</tr>
<tr>
<td>SP-D (pg/mL)</td>
<td>27810 (23356–38705)</td>
<td>35242 (23800–41848)</td>
</tr>
<tr>
<td>CRP (pg/mL)</td>
<td>449 (97–943)</td>
<td>237 (116–867)</td>
</tr>
</tbody>
</table>

Plasma

| CRP (mg/L) | 40 (33–61) | 32 (25–63) |

Data are median (IQR). IL, interleukin; TNFx, tumour necrosis factor α.

Figure 6 The effect of aspirin on bronchoalveolar lavage (BAL) and plasma thromboxane B2 (TXB2) after lipopolysaccharide inhalation (A) Plasma thromboxane B2 was reduced by aspirin treatment (n=12 placebo, n=20 aspirin). Difference in medians 3077 pg/mL, 95% CIs 755 to 7850; *p=0.003. (B) BAL thromboxane B2 was significantly reduced in the aspirin-treated cohort (n=20) compared with placebo (n=13). One outlier from the placebo group is not shown within the range of the graph (value >7000 pg/mL), but is included in statistical analysis presented. Difference in medians 41 pg/mL, 95% CIs 14.7 to 64.3; *p=0.003. BAL TXB2 is also significantly reduced in response to aspirin with this outlier excluded.)

The effect of high-dose versus low-dose aspirin on bronchoalveolar lavage (BAL) and plasma biomarkers

Table 4

Systemically a trend to reduction in neutrophil count occurred but did not reach statistical significance. Importantly, aspirin did not impair neutrophil phagocytic uptake of opsonised zymosan beads in vitro, implying aspirin may be used for anti-inflammatory effects while retaining the capacity to engulf pathogens. We recognise this assay did not measure aspirin vitrō activity.

Recent studies have highlighted the importance of platelet-neutrophil interaction in NETs formation. NETs have been shown to have bactericidal properties, which damage native
Aspirin significantly reduces neutrophilic inflammation in the human ex vivo lung perfusion model. Human lungs were ventilated and perfused ex vivo. Blood was preincubated with aspirin (n=5) or placebo (n=6) for 1 hour before adding to the lung perfusate and simultaneously injuring the lung with lipopolysaccharide (LPS) (6 mg). Bronchoalveolar lavage (BAL) was carried out 4 hours after injury. (A) Aspirin significantly reduces BAL neutrophilia. Neutrophils in BAL fluid were counted in cytospins. *p=0.03 for aspirin (n=5) versus placebo (n=6), MWU test. (B) Ventilated perfused isolated human lungs that were injured ex vivo with LPS had reduced injury as measured by lung injury score when treated with aspirin (n=5) versus placebo (n=6). y axis, AU, arbitrary units), *p=0.05 MWU test. (C) Illustrative histological sections of lung are shown. (i) and (iii) are placebo-treated lungs at low and high power, respectively; (ii) and (iv) are aspirin-treated lungs at low and high power. Scale bar represents 100 μm. Alveolar septal wall thickening, neutrophil recruitment and proteinaceous debris staining are less marked in the aspirin than the placebo-treated group. Quantification of lung injury score was carried out in a blinded manner to counter any potential bias in image selection.

Aspirin significantly reduces neutrophilic inflammation in the human ex vivo lung perfusion model. Human lungs were ventilated and perfused ex vivo. Blood was preincubated with aspirin (n=5) or placebo (n=6) for 1 hour before adding to the lung perfusate and simultaneously injuring the lung with lipopolysaccharide (LPS) (6 mg). Bronchoalveolar lavage (BAL) was carried out 4 hours after injury. (A) Aspirin significantly reduces BAL neutrophilia. Neutrophils in BAL fluid were counted in cytospins. *p=0.03 for aspirin (n=5) versus placebo (n=6), MWU test. (B) Ventilated perfused isolated human lungs that were injured ex vivo with LPS had reduced injury as measured by lung injury score when treated with aspirin (n=5) versus placebo (n=6). y axis, AU, arbitrary units), *p=0.05 MWU test. (C) Illustrative histological sections of lung are shown. (i) and (iii) are placebo-treated lungs at low and high power, respectively; (ii) and (iv) are aspirin-treated lungs at low and high power. Scale bar represents 100 μm. Alveolar septal wall thickening, neutrophil recruitment and proteinaceous debris staining are less marked in the aspirin than the placebo-treated group. Quantification of lung injury score was carried out in a blinded manner to counter any potential bias in image selection.
prevention or treatment of ARDS should be designed using lower-dose aspirin. We acknowledge that our models have limitations. In the healthy volunteer model of LPS inhalation, the nature of injury is mild and self-limiting compared with ARDS. BAL at a single time point does not capture the dynamic changes that take place in the inflamed alveoli in ARDS. The healthy participants lack comorbidities and poly-pharmacy. This was a pretreatment study designed to test the proof of concept that aspirin could reduce pulmonary inflammation. Due to the short-term nature of the model, a postinjury treatment would not have allowed us to test the effect of aspirin, particularly low-dose aspirin, as it takes >6 hours for 75 mg aspirin to achieve full platelet inhibition, and further downstream effects. Pretreatment is potentially relevant for those who can be identified as being at high risk of developing ARDS, and pre-existing aspirin therapy may have protective pulmonary effects for those undergoing surgery that predisposes to ARDS, for example, coronary artery bypass grafting or abdominal aortic aneurysm repair. Our model does not address whether aspirin withdrawal in the perioperative period increases the risk of pulmonary inflammation, and most studies looking at the effect of aspirin withdrawal perioperatively have focused on cardiovascular and bleeding outcomes rather than pulmonary complications.41-42 Although the EVLP model allows a greater induction of injury by using a higher LPS dose, it has a short life, preventing use of these lungs to study fibrotic or resolution phases of ARDS. The EVLP model lacks hepatopulmonary metabolism and a reticuloendothelial system, which may modulate the drug and inflammatory response, respectively. Additionally, the lungs have undergone a period of cold ischaemia and had been rejected for transplantation so there is potential variability in the baseline degree of injury. We try to minimise this by using only lungs that have intact fluid clearance at baseline and no gross evidence of haemorrhage, contusion or consolidation. Furthermore, the underlying mechanisms leading to ICU admission and brain death, and the treatments the donor may have received in ICU may lead to altered response to either LPS or aspirin. However, again we aimed to minimise any confounding from this by randomisation and blinding. In the EVLP model, the blood volume is diluted (1/10), which has the potential to affect rheology, intercellular interaction and cell recruitment to the lung. Unfortunately, it is not possible to obtain 1 L of blood from a single donor for research purposes to avoid this. In both models, the injury LPS is a bacterial antigen, rather than a live bacterium, and isolated TLR4 stimulation does not recapitulate the myriad of stimuli that drive ARDS in patients.

Nevertheless, both models have the advantage of being carried out in human tissues, proving prospectively that aspirin at clinically relevant doses can attenuate neutrophilic human alveolar inflammation, and histological alveolar injury, but does not affect epithelial barrier function. These data support the further testing of aspirin in clinical trials as an anti-inflammatory strategy for treatment of neutrophilic-driven pulmonary inflammatory diseases such as ARDS.

---

**Author affiliations**

1Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK
2School of Pharmacy, Queen’s University of Belfast, Belfast, Northern Ireland, UK
3Department of Medicine, University of California San Francisco, San Francisco, California, USA
4Northern Ireland Clinical Trials Unit, Royal Victoria Hospital, Belfast, UK
5Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle-upon-Tyne, UK
6Regional Intensive Care Unit, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK

**Acknowledgements** The authors thank the volunteers who participated in the study, the endoscopy staff and the Northern Ireland Clinical Research Facility at Belfast City Hospital, Ms C McDowell from the Northern Ireland CTU for statistical advice, and the funders (Intensive Care Society, UK, and Intensive Care Society of Ireland).

**Contributors** UH contributed to clinical study conduct, the ex vivo experiments, laboratory analyses, data analysis and manuscript preparation. MF contributed to ex vivo experiments, laboratory analyses, data analysis and manuscript preparation. MS contributed to study design, obtaining funding, clinical study, data analysis and manuscript preparation. RV contributed to study design, data analysis, AK, CS, EL, MRL, JS and AIJ contributed to laboratory analyses, data analysis and manuscript preparation. IMMN contributed to study design, lab analysis, data analysis and manuscript preparation. DMF-M contributed to study design, obtaining funding, clinical study, ex vivo experiments, data analysis and manuscript preparation. CMO contributed to study design, obtaining funding, clinical study, ex vivo experiments, lab analyses, data analysis and manuscript preparation.

**Funding** The UK Intensive Care Society and the Intensive Care Society of Ireland.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** ORECNI for clinical study, SREC at QUB for the EVLP study.

**Provenance and peer review** Not commissioned; externally peer reviewed.

---

**REFERENCES**

Critical care


